← Back to Search

Pharmacist-Led Video Consultation for Cancer Patients Starting Oral Medication

N/A

Waitlist Available

Led By Dawn Hershman, MD

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must take at least three prescribed, standing oral medications in addition to their newly prescribed anti-cancer drug

Patients must have received a prescription for a new oral anti-cancer drug within 4 weeks of enrollment, not administered as part of a clinical trial

Timeline

Screening 3 weeks

Treatment Varies

Follow Up within 30 days of the consultation

Awards & highlights

Study Summary

This trial will test if a one-time pharmacist-led video consultation can help patients starting an oral cancer drug by reducing the number of drugs they need to take, avoiding drug interactions, and increasing patient confidence.

Who is the study for?

This trial is for adults over 18 who have been prescribed a new oral anti-cancer drug and are taking at least three other regular medications. They must be able to use video technology or come to the hospital for a video visit, and speak English or Spanish.Check my eligibility

What is being tested?

The study tests a one-time pharmacist-led video consultation aimed at reviewing medications and educating patients about their new oral anti-cancer drugs. It aims to see if this can reduce medication conflicts and improve patient confidence in managing their treatment.See study design

What are the potential side effects?

Since the intervention is non-medical (a video consultation), there are no direct side effects related to drugs. However, participants may experience discomfort with using technology or anxiety about discussing their health over video.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am taking three or more daily prescription medications besides my cancer treatment.

Select...

I was prescribed a new oral cancer drug not part of a trial within the last 4 weeks.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Average of QTc prolongation

Proportion of subjects enrolled that complete the 30 minutes consultation and assessments

Rate of absorption interaction

Secondary outcome measures

Change in Medication Regimen Complexity Index (MRCI) before and after the consultation

Change in assess factors associated with OACD-related potential drug-drug interactions and medication inaccuracies

Change in mean score on the Acceptability of Intervention Measure (AIM) before and after the consultation

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Video consultation groupExperimental Treatment1 Intervention

Patients starting a new oral anti-cancer drug (OACD) will receive help to identify and manage potential drug-drug interactions alongside patient's oncologist through a one-time video consultation.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Video consultation

2017

N/A

~190

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor

1,431 Previous Clinical Trials

2,460,787 Total Patients Enrolled

Dawn Hershman, MDPrincipal InvestigatorColumbia University

12 Previous Clinical Trials

1,619 Total Patients Enrolled

Media Library

Video consultation Clinical Trial Eligibility Overview. Trial Name: NCT05299671 — N/A

Cancer Research Study Groups: Video consultation group

Cancer Clinical Trial 2023: Video consultation Highlights & Side Effects. Trial Name: NCT05299671 — N/A

Video consultation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05299671 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the aggregate figure of participants in this research?

"Affirmative. According to information on clinicaltrials.gov, this investigation is presently in search of volunteers with an initial posting date of June 22nd 2021 and a most recent edit occurring on March 17th 2022. The trial requires 50 individuals from one center to partake in the study."

Answered by AI

What objectives is this study striving to accomplish?

"This 30 minute trial will be used to evaluate the Rate of absorption interaction. Secondary goals include a shift in MRCI (Medication Regimen Complexity Index) and an assessment of the participants' self-efficacy regarding Medication Administration, both before and after the consultation. Additionally, there is interest in whether or not this consultation leads to a decrease in total medications/supplements taken by patients."

Answered by AI

Are there any open enrollment opportunities for this research study?

"Affirmative. Records listed on clinicaltrials.gov demonstrate that this medical experiment, which was posted on the 22nd of June 2021, is still actively recruiting participants. A total of 50 patients are needed to be enrolled at a solitary site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Video Consultation to Reduce Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs

Dawn L. Hershman 2021. "Video Consultation to Reduce Drug Interactions Among Patients Initiating Oral Anti-Cancer Drugs". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05299671.